Coronavirus Update: Oxford Racing Ahead With 8,000 Vaccinated In Phase III Trial
Plus: Eisai Joins RE-MAP Cap Study
• By Scrip Team
Generate a summary of this article
Listen to this article
Partnering with AstraZeneca, the Oxford team has opened up a clear lead in the race to enrol thousands of patients for late-stage safety and efficacy trials – but cannot make guarantees of when results might be ready.
Oxford, UK: The trials led by the university's Jenner Institute have already vaccinated 8,000 subjects
The University of Oxford team developing a coronavirus vaccine with AstraZeneca PLC is well ahead in the race to conduct late-stage trials, with 8,000 volunteers already dosed in its Phase III study.
This puts it far in advance of other frontrunners such as Moderna Inc. and Pfizer Inc., who are...
Keep up with the top pharma business news of the week. On the go.
Pfizer/BioNTech and Moderna rapidly adapted Comirnaty and Spikevax for the 2024-2025 season to address the KP.2 variant after the US FDA had advised them to target JN.1 in June.
When life hands a biotech company the equivalent of good grapes, the expectations are for its products to be the equivalent of fine wine. Before that Moderna looks likely to make lemonade.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.